Morgan Stanley is out with a research report on MAKO Surgical MAKO and it has an Equal-Weight rating on shares.
In a note to clients, Morgan Stanley writes, "In a healthcare environment characterized by weak utilization, MAKO delivered a solid quarter and increased the low end of procedure guidance. Inline system placements and accelerating utilization in a
seasonally weak 3Q were encouraging considering reported pressures on elective uni-knee procedures. System pricing appears stable adjusting for both hip upgrades and isolated conversion of non-commercial units."
Shares of MAKO closed at $33.34 yesterday/
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in